Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvoglustat - Amicus Therapeutics

Drug Profile

Duvoglustat - Amicus Therapeutics

Alternative Names: 1-deoxynojirimycin hydrochloride; AT-2220; AT2220-ERT combo therapy; AT2220-IV; Duvoglustat HCl; duvoglustat hydrochloride; duvoglustat-ERT combo therapy; HGT-3510

Latest Information Update: 24 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amicus Therapeutics
  • Class Alkaloids; Imino pyranoses; Pharmacological chaperones; Small molecules
  • Mechanism of Action Alpha-glucosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glycogen storage disease type II

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Aug 2015 Clinical development of duvoglustat is ongoing
  • 14 Feb 2013 Amicus Therapeutics plans a repeat-dose trial for Glycogen storage disease type II (IV formulation) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top